The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients
- 31 July 2003
- journal article
- Published by Elsevier in Kidney International
- Vol. 64 (1) , 295-304
- https://doi.org/10.1046/j.1523-1755.2003.00079.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Trends in Anemia Management among US Hemodialysis PatientsJournal of the American Society of Nephrology, 2002
- Potential cost savings of erythropoietin administration in end-stage renal diseaseThe American Journal of Medicine, 2002
- Epidemiology of Anemia Associated with Chronic Renal Insufficiency among Adults in the United StatesJournal of the American Society of Nephrology, 2002
- Should the Hematocrit (Hemoglobin) Be Normalized in Pre-ESRD or Dialysis Patients? Yes!Blood Purification, 2000
- Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathyKidney International, 2000
- Hematocrit levels and associated Medicare expendituresAmerican Journal of Kidney Diseases, 2000
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990